Goldman Sachs Group Inc Mi Nk Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.87 - $1.56 $1,678 - $3,009	1,929 Added 12.34%	17,561 $16,000
Q1 2024 May 15, 2024	SELL	$0.84 - $1.12 $3,717 - $4,956	-4,425 Reduced 22.06%	15,632 $14,000
Q4 2023 Feb 13, 2024	BUY	$0.88 - $1.21 $2,415 - $3,321	2,745 Added 15.86%	20,057 $21,000
Q3 2023 May 14, 2024	SELL	$1.1 - $2.09 $3,019 - $5,737	-2,745 Reduced 13.69%	17,312 $19,000
Q3 2023 Nov 14, 2023	BUY	$1.1 - $2.09 $327 - $622	298 Added 1.75%	17,312 $19,000
Q2 2023 May 14, 2024	SELL	$0.89 - $3.33 $2,708 - $10,133	-3,043 Reduced 15.17%	17,014 $35,000
Q2 2023 Aug 14, 2023	BUY	$0.89 - $3.33 $15,142 - $56,656	17,014 New	17,014 $35,000

848K

Ticker INKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,775,100
Market Cap $24.3M
Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.